Photo by nci from unsplash
The factor VIII mimetic emicizumab (Hemlibra, Hoffman‐la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment. Click to show full abstract
The factor VIII mimetic emicizumab (Hemlibra, Hoffman‐la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment.
Keywords:
coagulation tests;
treatment united;
treatment;
laboratory coagulation;
tests emicizumab;
emicizumab treatment
Journal Title: Haemophilia
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!